Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
A randomized, placebo-controlled, once weekly dose for four weeks, double blind study in
Healthy HIV-Uninfected Volunteers. Each of 3 consequent groups (120 mg, 200 mg and 280mg)
enrolls 6 active and 2 placebo subjects.